Sun Pharma, govt in PPP for malaria eradication

Sun Pharma, govt in PPP for malaria eradication
Deepak Patel New Delhi
Last Updated : Apr 26 2016 | 12:14 AM IST
India's largest pharmaceutical company Sun Pharmaceuticals on Monday entered into a public private partnership (PPP) with the Union and Madhya Pradesh governments for a campaign to ensure a malaria-free India.

In this partnership, the three stakeholders will establish a phased malaria eradication project for most endemic districts of Madhya Pradesh.

Moreover, the company and the Indian Council of Medical Research (ICMR) may enter a joint drug development programme to manufacture new patented drugs. ICMR comes under the Union ministry of health and family welfare.

Also Read

KEY TAKEAWAYS
  • The other stakeholder in the partnership is the Madhya Pradesh government
     
  • Mandla district in the state to be targeted first
 
  • Sun Pharma may also enter a joint drug development programme to manufacture new patented drugs
     
  • Aim of the PPP is to completely eradicate malaria in three to five years

  • "We are very open to such drug development. It would not be restricted to malaria-specific drugs. Most companies in India are not developing any new drugs. Sun Pharma can use our strengths (like clinical data) and we can use their manufacturing capability to develop new drugs," said Soumya Swaminathan, director general, ICMR.

    The first district in Madhya Pradesh to be targeted through this PPP would be Mandla, where 57 per cent of the population belong to Scheduled Tribes. The aim is to eradicate malaria in three to five years. Mandla district has a population of around one million and has over 12,000 villages.

    "The idea to start from one district is to understand what the problems are. Gaining knowledge from the experience, we would use it to roll out a larger programme once this project is successful," said Dilip Sanghvi, managing director, Sun Pharmaceuticals.

    One part of this PPP would be the malaria elimination in Mandla, while the other would be to prevent its re-introduction in the district later. For that, the company would publicly share data that it gathers from the district.

    The stakeholders will jointly undertake the eradication programme by setting up management and technical oversight for disease surveillance and elimination.

    *Subscribe to Business Standard digital and get complimentary access to The New York Times

    Smart Quarterly

    ₹900

    3 Months

    ₹300/Month

    SAVE 25%

    Smart Essential

    ₹2,700

    1 Year

    ₹225/Month

    SAVE 46%
    *Complimentary New York Times access for the 2nd year will be given after 12 months

    Super Saver

    ₹3,900

    2 Years

    ₹162/Month

    Subscribe

    Renews automatically, cancel anytime

    Here’s what’s included in our digital subscription plans

    Exclusive premium stories online

    • Over 30 premium stories daily, handpicked by our editors

    Complimentary Access to The New York Times

    • News, Games, Cooking, Audio, Wirecutter & The Athletic

    Business Standard Epaper

    • Digital replica of our daily newspaper — with options to read, save, and share

    Curated Newsletters

    • Insights on markets, finance, politics, tech, and more delivered to your inbox

    Market Analysis & Investment Insights

    • In-depth market analysis & insights with access to The Smart Investor

    Archives

    • Repository of articles and publications dating back to 1997

    Ad-free Reading

    • Uninterrupted reading experience with no advertisements

    Seamless Access Across All Devices

    • Access Business Standard across devices — mobile, tablet, or PC, via web or app

    More From This Section

    First Published: Apr 26 2016 | 12:06 AM IST

    Next Story